M&A Deal Summary |
|
---|---|
Date | 2021-04-15 |
Target | PPD |
Sector | Life Science |
Buyer(s) | Thermo Fisher Scientific |
Deal Type | Add-on Acquisition |
Deal Value | 17.4B USD |
Advisor(s) | J.P. Morgan Securities (Financial) Simpson Thacher & Bartlett (Legal) |
SEARCH BY
Try For Free 7-Day Free Trial
Category | Company |
---|---|
Founded | 1956 |
Sector | Test/Measurement Equipment |
Employees | 122,000 |
Revenue | 42.9B USD (2023) |
Thermo Scientific is a provider of analytical instruments, laboratory equipment, software, services, consumables and reagents for better workflow solutions spanning sample preparation, sample analysis, and data interpretation. Thermo Fisher Scientific was founded in 1956 and is based in Waltham, Massachusetts.
DEAL STATS | # |
---|---|
Overall | 57 of 62 |
Sector (Life Science) | 19 of 23 |
Type (Add-on Acquisition) | 50 of 55 |
State (North Carolina) | 4 of 4 |
Country (United States) | 35 of 38 |
Year (2021) | 3 of 4 |
Size (of disclosed) | 1 of 27 |
DATE | TARGET | DEAL TYPE | VALUE |
---|---|---|---|
2021-01-19 |
Mesa Biotech
San Diego, California, United States Mesa Biotech, Inc. is molecular diagnostic company develops and commercialize a PCR-based rapid point-of-care testing platform available for detecting infectious diseases including SARS-CoV-2, Influenza A and B, respiratory syncytial virus (RSV) and Strep A. Mesa Biotech is based in San Diego, California. |
Buy | $450M |
DATE | TARGET | DEAL TYPE | VALUE |
---|---|---|---|
2021-12-30 |
PeproTech
Cranbury, New Jersey, United States PeproTech is a provider of bioscience reagents known as recombinant proteins, including cytokines and growth factors. Recombinant proteins are used in the development and manufacturing of cell and gene therapies as well as in broader cell culture applications, especially for use in cellular research models. PeproTech was founded in 1988 and is based in Cranbury, New Jersey. |
Buy | $1.9B |